Daniel R. Chevallard's Net Worth
$111 Thousand
Who is Daniel R. Chevallard?
Daniel R. Chevallard does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Viracta Therapeutics, Inc., Regulus Therapeutics Inc., and LENZ Therapeutics, Inc..
SEC CIK
Daniel R. Chevallard's CIK is 0001706176
Past Insider Trading and Trends
2019 was Daniel R. Chevallard's most active year for acquiring shares with 5 total transactions. Daniel R. Chevallard's most active month to acquire stocks was the month of April. 2022 was Daniel R. Chevallard's most active year for disposing of shares, totalling 8 transactions. Daniel R. Chevallard's most active month to dispose stocks was the month of October. 2017 saw Daniel R. Chevallard paying a total of $49,999.95 for 154,945 shares, this is the most they've acquired in one year. In 2021 Daniel R. Chevallard cashed out on 43,356 shares for a total of $36,463.76, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Viracta Therapeutics, Inc. (VIRX) Snapshot price: $0.2301
CFO and COO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 12
| |||
Form 4
| +3.53% | 3.48K |
$0.73 | -$2,493.14 | 102.31K |
Feb 25 - Feb 27
| |||
Form 4
| +3.31% | 3.17K |
$0.50 | -$1,860.00 | 98.82K |
Nov 25 - Nov 28
| |||
Form 4
| +3.66% | 3.38K |
$1.45 | -$5,092.40 | 95.65K |
Aug 25 - Aug 28
| |||
Form 4
| +3.66% | 3.25K |
$1.42 | -$5,160.25 | 92.28K |
May 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 16
| |||
Form 4
| +3.84% | 3.29K |
$1.68 | -$6,050.64 | 89.02K |
Feb 25 - Feb 27
| |||
Form 4
| +4.08% | 3.36K |
$2.72 | -$9,605.63 | 85.73K |
Nov 25 - Nov 28
| |||
Form 4
| +4.09% | 3.23K |
$4.02 | -$14,679.21 | 82.38K |
Aug 25 - Aug 26
| |||
Form 4
| +4.34% | 3.29K |
$1.90 | -$6,836.36 | 79.14K |
May 25 - May 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 17
| |||
Form 4
| +3.96% | 2.89K |
$2.78 | -$11,112.44 | 75.85K |
Feb 25 - Feb 28
| |||
Form 4
| +9.28% | 6.2K |
$4.81 | -$36,463.76 | 72.96K |
Nov 25 - Nov 29
| |||
Form 4
| +17.62% | 10K |
$0.90 | $9,000.00 | 66.76K |
Sep 28
| |||
Form 4
| +26.81% | 12K |
$0.90 | $10,800.00 | 56.76K |
May 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Regulus Therapeutics Inc. (RGLS) Snapshot price: $1.48
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.31% | -2.67K |
$1.31 | -$3,500.39 | 77.87K |
Scheduled
|
Jul 1
| ||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
| +129.29% | 45.41K |
$1.41 | -$14,089.00 | 80.54K |
Scheduled
|
May 14 - May 15
| ||
Form 4
| -25.77% | -3.25K |
$0.98 | -$3,192.49 | 9.37K |
Scheduled
|
Apr 1
| ||
Form 4
| +655.31% | 30K |
$0.95 | $28,500.00 | 34.58K |
Feb 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 5
| |||
Form 4
| +1,229.19% | 54.95K |
$0.91 | $49,999.95 | 59.41K |
Jul 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
LENZ Therapeutics, Inc. (GRPH) No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.19K |
$15.68 | $49,987.84 | 3.19K |
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||